Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
Julia C F QuintanilhaJin WangAlexander B SibleyChen JiangAmy S EtheridgeFei ShenGuanglong JiangFlora MulkeyJai N PatelDaniel L HertzElizabeth Claire DeesHoward L McLeodMonica BertagnolliHope RugoHedy L KindlerWilliam Kevin KellyMark J RatainDeanna L KroetzKouros OwzarBryan P SchneiderDanyu LinFederico InnocentiPublished in: British journal of cancer (2021)
The results from the largest study of bevacizumab toxicity provide new markers of drug safety for further evaluations. SNP in KCNAB1 validated in an independent dataset provides evidence toward its clinical applicability to predict bevacizumab-induced hypertension. ClinicalTrials.gov Identifier: NCT00785291 (CALGB 40502); NCT00601900 (CALGB 40503); NCT00088894 (CALGB 80303) and NCT00110214 (CALGB 90401).